IDEX Corporation · IEX · FY2026 Q1 · Calendar Q2 2026

IDEX Beats on Q1 as HST Orders Surge 17%, Raises Full-Year Guidance

IDEX's Q1 FY2026 results mark an inflection from the modest 1-2% organic growth outlook maintained just one quarter ago. The Health & Science Technologies segment is the primary engine, with 17% organic order growth driven by AI-related data-center, semiconductor, and space-and-defense demand. A backlog build in HST now gives management visibility into growth through 2027, which supports the decision to raise full-year guidance to 3-4% organic growth and lift adjusted EPS to $8.35-$8.55. The 8020 strategic framework continues to deliver margin leverage, with adjusted EBITDA margin expanding 50 bps to 26%. While short-cycle industrial markets in FMT and FSDP remain soft, the divergence between high-growth HST and sluggish industrial segments is widening, and management is redirecting capital and CapEx toward HST capacity to capture that growth.

Reported Before market openNYSEIndustrials $17.30B market cap
100quality score

Earnings scorecard

Reported versus consensus
Reported EPS $2.00 Consensus $1.77
EPS surprise +13.0% Reported versus consensus
Reported revenue $886.9M Consensus $845.6M
Revenue surprise +4.9% Reported versus consensus

Market reaction

prior-close to event-session close
Stock move +5.8% Event window
SPY move -0.0% Same window
Abnormal move +5.8% Stock minus SPY
Volume 2.3× Versus trailing sessions
Subsequent drift -3.4% Up to 20 sessions
IEXSPY benchmark

Ask FN2 about IEX FY2026 Q1

Transcript, numbers and history already loaded

Free account. Your question opens in FN2 with this report's transcript and numbers attached.

Transcript intelligence

What changed

Organic revenue grew 5% year-over-year, up from the 1-2% pace guided in the prior quarter. Orders rose 10% organically, with HST orders surging 17%. Adjusted EBITDA margin expanded 50 basis points to 26%. EPS of $2.00 beat the $1.77 consensus by 13%, and revenue of $886.9M exceeded the $845.6M estimate by 4.9%. The stock rose 5.8% on the report before drifting 3.4% lower in subsequent sessions on 2.3x normal volume. Compared to the prior quarter, where guidance was merely maintained, management now raised both the organic growth and EPS outlook. CapEx outlook shifted from stable to increasing, with incremental investment directed at HST capacity. The IEEPA tariffs were repealed, and new administration tariffs are expected to have minimal net impact on IDEX.

Guidance delta

Management raised full-year organic revenue growth guidance from 1-2% to 3-4% and increased adjusted EPS guidance to $8.35-$8.55. This is an upgrade from the prior quarter, where guidance was maintained. Adjusted EBITDA margin target remains 26-27%. The $76M quarterly share repurchase program was reaffirmed. CapEx outlook shifted to increasing, focused on expanding HST capacity. Free cash flow conversion is targeted at or above 100% with $1.1 billion of liquidity.

Key takeaways

  • Organic revenue grew 5% YoY with 10% organic order growth, led by a 17% surge in HST orders.
  • EPS of $2.00 beat consensus by 13%; revenue of $886.9M beat by 4.9%.
  • Full-year organic growth guidance raised from 1-2% to 3-4%; adjusted EPS raised to $8.35-$8.55.
  • Adjusted EBITDA margin expanded 50 bps to 26%, with further expansion expected.
  • HST backlog build provides growth visibility through 2027.
  • Active bolt-on M&A pipeline with Mott, Muon, and Micro-LAM acquisitions extending capabilities in optics, filtration, and precision components.

Management priorities

  • Deploy capital to support HST growth and increase CapEx, especially in HST capacity.
  • Pursue bolt-on tuck-in acquisitions aligned with the 8020 platform strategy.
  • Maintain the $76M quarterly share repurchase program.
  • Improve margins of recently acquired businesses including Muon, Micro-LAM, and Mott.
  • Leverage the 8020 framework to expand in space, defense, and high-value fluid and optics markets.

Follow IEX with an agent that reads every filing, transcript, and price print. Free to start.

Try FN2 free

Earnings History

Estimate Beat Miss Match
IEX EPS earnings history estimate and actual scatter chart 10 reported fiscal quarters and 2 future estimate-only quarters. Q4 '23 estimate $1.78 Q4 '23 actual $1.83, beat Q1 '24 estimate $1.76 Q1 '24 actual $1.88, beat Q2 '24 estimate $2.04 Q2 '24 actual $2.06, beat Q3 '24 estimate $1.89 Q3 '24 actual $1.90, match Q2 '25 estimate $2.00 Q2 '25 actual $2.07, beat Q3 '25 estimate $1.93 Q3 '25 actual $2.03, beat Q4 '25 estimate $2.04 Q4 '25 actual $2.10, beat Q1 '26 estimate $1.77 Q1 '26 actual $2.00, beat Q2 '26 estimate $2.11 Q2 '26 actual $2.32, beat Q3 '26 estimate $2.24 Q3 '26 actual $2.33, beat Q4 '26 estimate $2.20 Q1 '27 estimate $2.18
Show less

Analyst Consensus ?

ConsensusBuy29 ratings
Bullish1551.7%
Neutral1448.3%
Bearish00.0%

Analyst 52W Price Targets

$237.71Current
$205Low
$244.6Average
$280High

Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 29, 2026. Not an FN2 forecast.

Firm-level rating actions

FMP grade actions identify the grading firm, not a named analyst.

FirmRatingPrior ratingActionDate
Oppenheimer Outperform OutperformMaintainOct 21, 2026
RBC Capital Outperform OutperformMaintainOct 14, 2026
Mizuho Outperform NeutralUpgradeAug 12, 2026
DA Davidson Neutral NeutralMaintainAug 6, 2026
Argus Research Buy BuyMaintainAug 6, 2026
Show 24 more rating actions

Named analyst price targets

Upside is calculated against the persisted current price $237.7. FMP does not supply a rating on these named-analyst rows.

FirmAnalyst52W targetPrice when postedUpsideDate
Stifel NicolausAnalyst unavailable$267$235.55 +12.3%Oct 19, 2026
OppenheimerAnalyst unavailable$270$225.66 +13.6%Sep 9, 2026
Vertical ResearchJeffrey Sprague$250$223.74 +5.2%Sep 8, 2026
Mizuho SecuritiesBrett Linzey$280$237.31 +17.8%Aug 11, 2026
D.A. DavidsonAnalyst unavailable$240$234.88 +1.0%Aug 6, 2026
See 38 more

Track every rating change on IEX the moment it posts. Free to start.

Start free

Company context

Snapshot as of publication

IDEX Corporation is an international enterprise specializing in engineered solutions across diverse sectors. The company operates through three primary business units: Fluid & Metering Technologies (FMT), Health & Science Technologies (HST), and Fire & Safety/Diversified Products (FSDP). The FMT division is responsible for the design, production, and distribution of a range of fluid-handling equipment, including positive displacement pumps, flow meters, and injectors, alongside offering flow monitoring and related services. Its applications span the food, chemical, general industrial, water management, agricultural, and energy industries. Under the HST umbrella, IDEX develops and supplies precision components and systems for health and scientific applications.…

Historical context

All IEX earnings

Industrials peers this season

Latest reports in the same sector

Latest beats and misses

Who reports next

Get the IEX recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Sources

  1. Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
  2. FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
  3. Polygon adjusted daily market bars · 2026-07-31T08:01:01.075040+00:00
  4. Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-07-31T08:01:01.072281+00:00

Methodology

Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.

Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.

Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.

By FN2 Research · Updated · As of 2026-07-31. For educational purposes only; not investment advice.